{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Loo SK"],"funding":["National Institute of Health","NCI NIH HHS"],"pagination":["127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11465729"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<h4>Background</h4>Lung cancer, a leading global cause of cancer-related mortality, necessitates enhanced prognostic markers for improved treatment outcomes. We have previously shown a tumor suppressive role of cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1), which is targeted for degradation upon phosphorylation at S14 (pCASTOR1) in multiple types of cancer. This study focuses on the predictive value of pCASTOR1 in lung adenocarcinoma (LUAD) patients with KRAS mutations.<h4>Results</h4>Employing a newly developed pCASTOR1 specific antibody, we found that tumor cells exhibited significantly elevated pCASTOR1 scores compared to non-tumor cells (P < 0.05). Higher pCASTOR1 scores predicted poorer overall survival (OS) (HR = 3.3, P = 0.0008) and relapse-free survival (RFS) (HR = 3.0, "],"journal":["Cell & bioscience"],"pubmed_title":["CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma."],"pmcid":["PMC11465729"],"funding_grant_id":["P30 CA047904","CA278812","R01 CA124332","CA124332","CA284554","R01 CA284554","R01 CA096512","R01 CA278812","CA096512"],"pubmed_authors":["Loo SK","Sica G","Gao SJ","Huang Y","Li T","Chen L","Stabile LP","Gaither-Davis A","Wang X","Burns TF"],"additional_accession":[]},"is_claimable":false,"name":"CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma.","description":"<h4>Background</h4>Lung cancer, a leading global cause of cancer-related mortality, necessitates enhanced prognostic markers for improved treatment outcomes. We have previously shown a tumor suppressive role of cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1), which is targeted for degradation upon phosphorylation at S14 (pCASTOR1) in multiple types of cancer. This study focuses on the predictive value of pCASTOR1 in lung adenocarcinoma (LUAD) patients with KRAS mutations.<h4>Results</h4>Employing a newly developed pCASTOR1 specific antibody, we found that tumor cells exhibited significantly elevated pCASTOR1 scores compared to non-tumor cells (P < 0.05). Higher pCASTOR1 scores predicted poorer overall survival (OS) (HR = 3.3, P = 0.0008) and relapse-free survival (RFS) (HR = 3.0, ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-14T05:23:06.564Z","creation":"2025-04-04T02:17:06.553Z"},"accession":"S-EPMC11465729","cross_references":{"pubmed":["39385301"],"doi":["10.1186/s13578-024-01307-4"]}}